Karen Schneck

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 10

Top Topics

Top Venues

CPT: pharmacometrics & systems pharmacology

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Karen Schneck, Shweta Urva
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Karen Schneck, Shweta Urva
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: pharmacometrics & systems pharmacology (2024)
Shweta Urva, Joshua A Levine, Karen Schneck, Cheng Cai Tang
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide. Current medical research and opinion 40 (4) (2024)
Shweta Urva, Joshua A Levine, Karen Schneck, Cheng Cai Tang
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide. Current medical research and opinion 40 (4) (2024)
Karen Schneck, Shweta Urva
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Karen Schneck, Shweta Urva
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Shweta Urva, Joshua A Levine, Karen Schneck, Cheng Cai Tang
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide. Current medical research and opinion 40 (4) (2024)
Karen Schneck, Shweta Urva
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Karen Schneck, Shweta Urva
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Shweta Urva, Joshua A Levine, Karen Schneck, Cheng Cai Tang
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide. Current medical research and opinion (2024)